Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBIT Margin (2022 - 2025)

Cannabis Bioscience International Holdings' EBIT Margin history spans 3 years, with the latest figure at 180.0% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 9969.0% year-over-year to 180.0%; the TTM value through Nov 2025 reached 341.41%, down 23873.0%, while the annual FY2025 figure was 139.05%, 5631.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 180.0% at Cannabis Bioscience International Holdings, up from 309.02% in the prior quarter.
  • Across five years, EBIT Margin topped out at 39.06% in Q2 2024 and bottomed at 865.54% in Q1 2025.
  • The 3-year median for EBIT Margin is 275.89% (2023), against an average of 330.49%.
  • The largest annual shift saw EBIT Margin surged 55325bps in 2024 before it plummeted -34831bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 143.37% in 2023, then skyrocketed by 44bps to 80.31% in 2024, then crashed by -124bps to 180.0% in 2025.
  • Per Business Quant, the three most recent readings for CBIH's EBIT Margin are 180.0% (Q4 2025), 309.02% (Q3 2025), and 385.91% (Q2 2025).